Pure Global AI
NCT06138756Completed

Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)

TheranicaClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Migraine
Drug/Device/Intervention
Nerivio
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Theranica
Location
Netanya, Israel
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Oct 20, 2023
Enrollment
52 participants
Primary outcome

Device Related Adverse Events

Summary

Migraine is a prevalent neurological disorder that severely impacts both children and
 adolescents, causing significant disability. Remote Electrical Neuromodulation (REN) is a
 nonpharmacological, prescribed, wearable device, FDA-cleared for acute and/or preventive
 treatment of migraine with or without aura in patients 12 years or older. Multiple studies
 have shown that REN has high safety, tolerability, and efficacy in adults and adolescents.
 This study aims to evaluate REN's real-world safety and efficacy in pre-adolescents, 9-11
 years old.

ICD-10 classifications
MigraineOther migraineMigraine, unspecifiedComplicated migraineHeadache
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06138756
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06138756 through Pure Global AI's free database. This phase not specified trial is sponsored by Theranica and is currently Completed. The study focuses on Migraine. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.